On 9 July 2001, orphan designation (EU/3/01/044) was granted by the European Commission to Aventis Behring GmbH, Germany, for human alpha-1-proteinase inhibitor (respiratory use) for the treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency.
The sponsor changed name to ZLB Behring GmbH in February 2005 and subsequently to CSL Behring GmbH in April 2007.
Human alpha1-proteinase inhibitor
Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency
|Orphan designation status||
|EU designation number||
|Date of designation||
CSL Behring GmbH
Tel. + 49 6421 3912
Documents related to this orphan designation evaluation
EU/3/01/044: Public summary of positive opinion for orphan designation of human alpha1-proteinase inhibitor (respiratory use) for the treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency (PDF/109.94 KB)
First published: 24/02/2009
Last updated: 06/05/2011
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: